Skip to main
INSM
INSM logo

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 31 analyst ratings
Buy
Strong Buy 39%
Buy 55%
Hold 3%
Sell 3%
Strong Sell 0%

Bulls say

Insmed Inc. showcases a promising trajectory for growth, underscored by the potential of its flagship product, ARIKAYCE, with projected global revenues reaching between $405 million to $425 million by 2025, based on steady sales growth and ongoing commercial expansion. The anticipated launch of Brensocatib is expected to be robust, with significant demand anticipated among healthcare professionals; this could pave the way for peak sales estimated at $8.2 billion, driven largely by the absence of effective treatment options for bronchiectasis. Furthermore, with an expanded commercial infrastructure and the potential for label expansions for both ARIKAYCE and Treprostinil Palmitil Inhalation Powder, Insmed's pipeline is positioned to realize multi-billion dollar value, reinforcing a fundamentally positive outlook on the company's growth trajectory.

Bears say

Insmed Inc faces a challenging financial outlook, characterized by a substantial net loss of $913.8 million for FY24, coupled with ongoing operational expenses that outpace income potential from its current product lineup. Key risks include potential safety signals from existing and pipeline drugs, regulatory approval uncertainties, and commercial viability challenges that could significantly hinder revenue generation. Furthermore, the company’s heavy reliance on successful clinical trials and the commercialization of its products amidst competitive pressures may exacerbate its financial instability, raising concerns about its ability to sustain operations and meet debt obligations.

Insmed (INSM) has been analyzed by 31 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 55% recommend Buy, 3% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 31 analysts, Insmed (INSM) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.